Synch has assisted Lipidor AB

Lipidor AB (Nasdaq First North:LIPI) today announced that the company has signed an exclusive licensing agreement with Cannassure Therapeutics Ltd. (TASE:CSURE), an Israeli company specializing in the development and manufacture of innovative medicinal cannabis products. The license agreement was drafted and negotiated by Synch´sUnder the agreement, Cannassure has the exclusive right to use Lipidor’s proprietary drug delivery technology AKVANO®in medicinal cannabis products for the treatment of selected indications such as psoriasis, atopic dermatitis, pain and lesions. Lipidor receives a royalty of 15-17.5% on future product sales. When a predetermined accumulated sales volume is achieved, Lipidor will receive an additional milestone payment in the form of 1% of the share capital value of Cannassure, up to a maximum of EUR 350,000. Lipidor’s projection is that this milestone compensation will be paid within a two-year period.

Ola Holmlund, CEO of Lipidor, says: “Lipidor is very pleased with our collaboration with Synch and the high level of legal expertise that Sara Sparring possesses. Synch/Sara has played an important role in getting this agreement together. During the negotiation process, we have received invaluable support, which has been crucial to reaching this successful agreement.”

More from our team